Skip to main content

Advertisement

SpringerLink
Log in

Molecular targeting therapy for pancreatic cancer

  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Pancreatic carcinogenesis is driven by multiple genetic and epigenetic changes. The epidermal growth factor receptor (EGFR) and its downstream signaling pathways, Ras-Raf-MEK-ERK axis, play important roles in pancreatic cancer development. The phosphoinositol 3 kinase (PI3 K)/Akt and the nuclear factor κB (NF-κB) pathways control both proliferation and resistance to apoptosis of pancreatic cancer. The role of cyclooxygenase (COX) and lipoxygenase (LOX) in the development of pancreatic cancer has been made known recently. The elucidation of these molecular events has led to several distinct therapeutic advances, including therapies that target EGFR, the Ras-Raf-MEK-ERK axis, the COX-2 and LOX pathways, and others. Many novel agents have been developed and are undergoing clinical investigation, such as monoclonal antibodies against EGFR, tyrosine kinase inhibitors (TKIs), farnesyl transferase inhibitors (FTIs), Bay43-9006, CI-1040, CCI-779, celecoxib, and LY293111. This review highlights recent advances in the development of these agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abbruzzese J, Rosenberg A, Xiong Q, LoBuglio A, Schmidt W, Wolff R, Needle M, Waksal H (2001) A phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer (abstract 518). Proc Am Soc Clin Oncol 20

  2. Adrian TE, Ding XZ, Tong WG (2001) The mitogenic effect of 5-lipoxygenase metabolite, 5-HETE on pancreatic cancer cell proliferation through activation of multiple signaling pathways. FASEB J 15:A1163

    Google Scholar 

  3. Aggarwal BB, Kumar A, Bharti AC (2003) Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23(1A):363

    CAS  PubMed  Google Scholar 

  4. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53:549

    CAS  PubMed  Google Scholar 

  5. Alroy I, Yarden Y (1988) The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 410:83

    Article  Google Scholar 

  6. Arlt A, Gehrz A, Muerkoster S, Vorndamm J, Kruse ML, Folsch UR, Schafer H (2003) Role of NF-kappaB and Akt/PI3 K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 22:3243

    Article  CAS  PubMed  Google Scholar 

  7. Armistead D, Harding MW (1993) Immunophilins and immunosuppressive drug action. Ann Rep Med Chem 28:207

    CAS  Google Scholar 

  8. Banerji U, O’Donnell A, Scurr M, Benson C, Stapleton S, Raynaud F, Clarke F, Turner A, Workman P, Judson I, Block E (2003) A pharmacokinetically (PK)–pharmacodynamically (PD) guided phase I trial of the heat shock protein 90 (HSP90) inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) (abstract 797). Proc Am Soc Clin Oncol 22:199

    Google Scholar 

  9. Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N (2002) Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 277:39858

    Article  CAS  PubMed  Google Scholar 

  10. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ (2002) Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 1:989

    CAS  PubMed  Google Scholar 

  11. Brown EJ, Albers MW, Shin TB, Khikawa K, Keith CT, Lane WS, Shreiber SL (1994) A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369:756

    Google Scholar 

  12. Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McConkey DJ, Evans DB, Abbruzzese JL, Hicklin DJ, Radinsky R (2000) Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 5:1936

    Google Scholar 

  13. Buchsbaum DJ, Bonner JA, Grizzle WE, Stackhouse MA, Carpenter M, Hicklin DJ, Bohlen P, Raisch KP (2002) Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys 4:1180

    Article  Google Scholar 

  14. Cantley LC (2003) The phosphoinositide 3-kinase pathway. Science 5573:1655

    Google Scholar 

  15. Chan S, Scheulen ME, Johnston S, Mross K, Piccart M, Hess D, Bouxin N, Azli N (2003) Phase 2 study of two dose levels of CCI-779 in locally advanced or metastatic breast cancer (MBC) failing prior anthracycline and/or taxane regimens (abstract 774). Proc Am Soc Clin Oncol 22:193

    Google Scholar 

  16. Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, Alpaugh RK, Beard M, Lewis NL, McLaughlin S, Rogatko A, Perez-Ruixo JJ, Thistle AM, Verhaeghe T, Wang H, Weiner LM, Wright JJ, Hudes GR, Merepol NJ (2003) Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol 21:1301

    Article  PubMed  Google Scholar 

  17. Davis CG, Gallo ML, Corvalan JRF (2003) Transgenic mice as a source of fully human antibodies for the treatment of cancer. Cancer Metastasis Rev 18:421

    Article  Google Scholar 

  18. Ding XZ, Iversen P, Cluck MW, Knezetic JA, Adrian TE (1999) Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. Biochem Biophys Res Commun 261:218

    Article  CAS  PubMed  Google Scholar 

  19. Ding XZ, Tong WG, Adrian TE (2000) Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res 4:2625

    Google Scholar 

  20. Ding XZ, Hennig R, Adrian TE (2003) Lipoxygenase and cyclooxygenase metabolism: new insights in treatment and chemoprevention of pancreatic cancer. Mol Cancer 1:10

    Article  Google Scholar 

  21. Ding XZ, Tong WG, Adrian TE (2003) 12-Lipoxygenase metabolite, 12(S)-HETE stimulates pancreatic cancer cell proliferation. Involvement of tyrosine phosphorylation and MEK/ERK activation. Int J Cancer 94:630

    Article  Google Scholar 

  22. Dong M, Nio Y, Guo KJ, Tamura K, Tian YL, Dong YT (1998) Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. Anticancer Res 18:4613

    CAS  PubMed  Google Scholar 

  23. Dong QG, Sclabas GM, Fujioka S, Schmidt C, Peng B, Wu T, Tsao MS, Evans DB, Abbruzzese JL, McDonnell TJ, Chiao PJ (2003) The function of multiple IkappaB:NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene 21:6510

    Article  Google Scholar 

  24. End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S, Devine A, Wouters W, Bowden C (2001) Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 61:131

    CAS  PubMed  Google Scholar 

  25. Fujioka S, Sclabas GM, Schmidt C, Frederick WA, Dong QG, Abbruzzese JL, Evans DB, Baker C, Chiao PJ (2003) Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res 9:346

    CAS  PubMed  Google Scholar 

  26. Geoerger B, Kerr K, Tang CB, Fung KM, Powell B, Sutton LN, Phillips PC, Janss AJ (2001) Antitumor activity of the rapamycin analogue CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 61:1527

    CAS  PubMed  Google Scholar 

  27. Gilmore TD, Koedood M, Piffat KA, White D (1997) Rel/NF-κB/IκB proteins and cancer. Oncogene 14:1367

    Google Scholar 

  28. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J (1995) Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1:1311

    CAS  PubMed  Google Scholar 

  29. Hennig R, Ding XZ, Tong WG, Schneider MB, Standop J, Friess H, Buchler MW, Pour PM, Adrian TE (2002) 5-Lipoxygenase and leukotriene B4 receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am J Pathol 161:421

    CAS  PubMed  Google Scholar 

  30. Hidalgo M, Atkins MB, Stadler WM, Logan T, Dutcher JP, Hudes G, Marshall B, Liou SH, Dukart G (2003) A randomized double-blind phase 2 study of intravenous (IV) CCI-779 administered weekly to patients with advanced renal cell carcinoma (RCC): prognostic factor analysis (abstract 804). Proc Am Soc Clin Oncol 22:201

    Google Scholar 

  31. Huang S, Mills L, Mian B, Tellez C, McCarty M, Yang XD, Gudas JM, Bar-Eli M (2002) Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol 161:125

    CAS  PubMed  Google Scholar 

  32. Kollmannsberger C, Schittenhelm M, Honecker F, Rosen O, Tillner J, Kanz L, Bokemeyer C (2003) Epidermal growth factor receptor (EGFR) antibody EMD 72000 in combination with paclitaxel (P) in patients (pts) with EGFR-positive advanced non-small cell lung cancer (NSCLC): a phase-I study (abstract 2520). Proc Am Soc Clin Oncol 22:627

    Google Scholar 

  33. Le X, Shi Q, Wang B, Xiong Q, Qian C, Peng Z, Li XC, Tang H, Abbruzzese JL, Xie K (2000) Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. J Interferon Cytokine Res 20:935

    Article  CAS  PubMed  Google Scholar 

  34. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL (2002) Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 62:625

    CAS  PubMed  Google Scholar 

  35. Lemoine NR, Hughes CM, Barton CM, Poulsom R, Jeffery RE, Kloppel G, Hall PA, Gullick WJ (1992) The epidermal growth factor receptor in human pancreatic cancer. J Pathol 166:7

    CAS  PubMed  Google Scholar 

  36. Macdonald JS, Chansky K, Whitehead R, Wade J, Giguere J, Abbruzzese JL (2002) A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest Oncology Group (SWOG) (abstract 548). Proc Am Soc Clin Oncol 21

    Google Scholar 

  37. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K (2000) Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60:1306

    CAS  PubMed  Google Scholar 

  38. Mendez MJ, Green LL, Corvalan JRF, Jia XC, Maynard-Currie CE, Yang XD, Gallo ML, Louie DM, Lee DV, Erickson KL, Luna J, Roy CM, Abderrahim H, Kirschenbaum F, Noguchi M, Smith DH, Fukushima A, Hales JF, Klapholz S, Finer MH, Davis CG, Zsebo KM, Jakobovits A (1997) Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet 15:146

    CAS  PubMed  Google Scholar 

  39. Mian BM, Dinney CP, Bermejo CE, Sweeney P, Tellez C, Yang XD, Gudas JM, McConkey DJ, Bar-Eli M (2002) Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clin Cancer Res 9:3167

    Google Scholar 

  40. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA (1999) Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 59:4356

    CAS  PubMed  Google Scholar 

  41. Morgan JA, Bukowski RM, Xiong H, Clark J, Zacharchuk C, Plazney D, Pelley R, Fuchs C (2003) Preliminary report of a phase 1 study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), given in combination with gemcitabine to patients with advanced pancreatic cancer (abstract 788). Proc Am Soc Clin Oncol 22:197

    Google Scholar 

  42. Motojima K, Urano T, Nagata Y, Shiku H, Tsunoda T, Kanematsu T (1991) Mutations in the Kirsten-ras oncogene are common but lack correlation with prognosis and tumor stage in human pancreatic carcinoma. Am J Gastroenterol 86:1784

    CAS  PubMed  Google Scholar 

  43. Murphy LO, Cluck MW, Lovas S, Otvos F, Murphy RF, Schally AV, Permert J, Larsson J, Knezetic JA, Adrian TE (2001) Pancreatic cancer cells require an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditions. Br J Cancer 84:926

    Article  CAS  PubMed  Google Scholar 

  44. Nawrocki ST, Bruns CJ, Harbison MT, Bold RJ, Gotsch BS, Abbruzzese JL, Elliott P, Adams J, McConkey DJ (2002) Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 1:243

    Google Scholar 

  45. Ng SS, Tsao MS, Chow S, Hedley DW (2000) Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 60:5451

    CAS  PubMed  Google Scholar 

  46. Ng SS, Tsao MS, Nicklee T, Hedley DW (2001) Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res 7:3269

    CAS  PubMed  Google Scholar 

  47. Overholser JP, Prewett MC, Hooper AT, Waksal HW, Hicklin DJ (2000) Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 89:74

    Article  CAS  PubMed  Google Scholar 

  48. Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, Neshat M, Wang H, Yang L, Gibbons J, Frost P, Dreisbach V, Blenis J, Gaciong Z, Fisher P, Sawyers C, Hedrick-Ellenson L, Passons R (2001) An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice. Proc Natl Acad Sci U S A 98:10320

    Google Scholar 

  49. Presta LG (1992) Antibody engineering. Curr Opin Biotechnol 3:394

    CAS  PubMed  Google Scholar 

  50. Ryan DP, Elder JP, Winkelmann J, Lynch T, Supko J, Appleman LJ, Fidias P, Enzinger P, Zhu A, Kinchla N, Esseltine D, Baldwin A, Elliott P, Adams J, Kauffman M, Schenkein D, Cusack J (2002) Pharmacokinetic and pharmacodynamic phase I study of PS-341 and gemcitabine in patients with advanced solid tumors (abstract 379). Proc Am Soc Clin Oncol 21

  51. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH (1983) Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1:511

    CAS  PubMed  Google Scholar 

  52. Schwartz GK, Budman DR, Endres S, Welch M, O’Reilly E, Barile-Thiem B, Brail LH, De Alwis DP, Cleverly A, Weitzman A (2002) Phase I and pharmacokinetic study of LY293111, an orally available small molecule known to be an LTB4 receptor antagonist, 5-lipoxygenase inhibitor and peroxisome proliferator activated receptor-gamma agonist (PPARγ) (abstract 343). Proc Am Soc Clin Oncol 21

  53. Sclabas GM, Fujioka S, Schmidt C, Fan Z, Evans DB, Chiao PJ (2003) Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C225. J Gastrointest Surg 7:37

    Article  PubMed  Google Scholar 

  54. Sebti SM, Hamilton AD (2000) Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues. Expert Opin Investig Drugs 9:2767

    CAS  PubMed  Google Scholar 

  55. Sekulic A, Hudson CC, Homme JL, Yin P, Offerness DM, Karnitz LM, Abraham RT (2000) A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 60:3504

    CAS  PubMed  Google Scholar 

  56. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, Pirmohamed M, Marnett LJ, Gescher AJ, Steward WP (2001) Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 7:1894

    CAS  PubMed  Google Scholar 

  57. Shi Q, Abbruzzese JL, Huang S, Fidler IJ, Xiong Q, Xie K (1999) Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res 5:3711

    CAS  PubMed  Google Scholar 

  58. Siu L, Awada A, Takimoto CH, Moore MJ, Piccart M, Fiander W, Lathia C, Petrenciuc O (2003) Phase I study of oral raf-1 kinase inhibitor BAY 43-9006 with gemcitabine in patients with advanced solid tumors (abstract 828). Proc Am Soc Clin Oncol 22:207

    Google Scholar 

  59. Smith SE, Burris HA, Loehrer PJ, Sweeny C, Gordon M, Obregon Y, Dragovich T (2003) Preliminary report of a phase II trial of gemcitabine combined with celecoxib for advanced pancreatic cancer (abstract 1502). Proc Am Soc Clin Oncol 22:374

    Google Scholar 

  60. Stevenson JP, Petrylak DP, K Feit K, Shelton G, Gallagher M, Haller DH, Sun WJ, Kindsfather S, Brail LH, de Alwis DP, Weitzman A Jr, O’Dwyer PJ (2002) Phase I and pharmacokinetic trial of LY293111 in combination with gemcitabine (abstract 2140). Proc Am Soc Clin Oncol 21

  61. Theodore C, Geoffrois L, Vermorken JB, Caponigro F, Fiedler W, Chollet P, Ravaud A, Baron B, Lacombe D, Fumoleau P (2003) A phase II multicentre study of SCH66336 in combination with gemcitabine as second line treatment in patients with advanced/metastatic urothelial tract tumor (abstract 1667). Proc Am Soc Clin Oncol 22:415

    Google Scholar 

  62. Tong WG, Ding XZ, Hennig R, Witt RC, Standop J, Pour PM, Adrian TE (2002) Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Clin Cancer Res 8:3232

    CAS  PubMed  Google Scholar 

  63. Tseng WW, Deganutti A, Chen MN, Saxton RE, Liu CD (2002) Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer. J Gastrointest Surg 6:838

    Article  PubMed  Google Scholar 

  64. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow RA, Masferrer JL, Woerner BM, Koki AT, Fahey TJ 3rd (1999) Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 59:987

    CAS  PubMed  Google Scholar 

  65. Ullrich A, Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61:203

    CAS  PubMed  Google Scholar 

  66. Van Cutsem E, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Neumann H, Safran H, Humblet Y, van de Velde H, Ma Y, Von Hoff D (2002) Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer (PC) (abstract 517). Proc Am Soc Clin Oncol 21

  67. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ (1999) The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 5:119

    CAS  PubMed  Google Scholar 

  68. Waterhouse DM, Rinehart J, Adjei AA, Hecht JR, Natale RB, Lorusso PM, Asbury PC, Hamid O, Gulyas S, Meyer MB (2003) A phase 2 study of an oral MEK inhibitor, CI-1040, in patients with advanced nonsmall-cell lung, breast, colon, or pancreatic cancer (abstract 816). Proc Am Soc Clin Oncol 22:204

    Google Scholar 

  69. Wu X, Rubin M, Fan Z, De Blasio T, Soos T, Koff A, Mendelsohn J (1996) Involvement of p27kip1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 12:1397

    CAS  PubMed  Google Scholar 

  70. Xiong HQ, Du M, Wolff RA, Lenzi R, Dumas P, Lassere Y, Plunkett W, Abbruzzese JL (2002) Pharmacology study of celecoxib in combination with gemcitabine for advanced pancreatic cancer (abstract 448). Proc Am Soc Clin Oncol 21

  71. Yamada KM, Araki M (2001) Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J Cell Sci 114:2375

    Google Scholar 

  72. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG, Korc M (1993) Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 13:565

    CAS  PubMed  Google Scholar 

  73. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG (2001) Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 38:17

    Article  CAS  PubMed  Google Scholar 

  74. Yip-Schneider MT, Barnard DS, Billings SD, Cheng L, Heilman DK, Lin A, Marshall SJ, Crowell PL, Marshall MS, Sweeney CJ (2000) Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 21:139

    Article  CAS  PubMed  Google Scholar 

  75. Yip-Schneider MT, Sweeney CJ, Jung SH, Crowell PL, Marshall MS (2001) Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther 298:976

    CAS  PubMed  Google Scholar 

  76. Yip-Schneider MT, Wiesenauer CA, Schmidt CM (2003) Inhibition of the phosphatidylinositol 3′-kinase signaling pathway increases the responsiveness of pancreatic carcinoma cells to sulindac. J Gastrointest Surg 7:354

    Article  PubMed  Google Scholar 

  77. Zhang X, Shu L, Hosio H, Murti KG, Houghton PJ (2002) Predominant nuclear localization of mammalian target of rapamycin in normal and malignant cells in culture. J Biol Chem 277:28127

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastrointestinal Medical Oncology, Unit 426, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA

    Henry Q. Xiong

Authors
  1. Henry Q. Xiong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Henry Q. Xiong.

Additional information

This work was presented at the 19th Bristol-Myers Squibb Nagoya International Cancer Treatment Symposium, “State of the Arts for Digestive Organs”, 14–15 November 2003, Nagoya, Japan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xiong, H.Q. Molecular targeting therapy for pancreatic cancer. Cancer Chemother Pharmacol 54 (Suppl 1), S69–S77 (2004). https://doi.org/10.1007/s00280-004-0890-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-004-0890-2

Keywords

Search

Navigation